Insufficient scRNA-seq data for expression of HTR1B at single-cell level.
Insufficient scRNA-seq data for expression of HTR1B at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
blood vessel | 99% | 719.02 | 1323 / 1335 | 0% | 0 | 0 / 0 |
bladder | 81% | 135.19 | 17 / 21 | 10% | 0.30 | 52 / 504 |
stomach | 62% | 84.72 | 221 / 359 | 26% | 1.11 | 74 / 286 |
esophagus | 56% | 87.17 | 810 / 1445 | 19% | 0.53 | 35 / 183 |
brain | 54% | 78.24 | 1423 / 2642 | 18% | 0.41 | 128 / 705 |
pancreas | 1% | 0.58 | 3 / 328 | 57% | 1.86 | 102 / 178 |
lung | 45% | 32.14 | 259 / 578 | 10% | 0.39 | 115 / 1155 |
uterus | 41% | 49.87 | 69 / 170 | 5% | 0.28 | 23 / 459 |
adipose | 40% | 43.65 | 483 / 1204 | 0% | 0 | 0 / 0 |
skin | 35% | 137.61 | 631 / 1809 | 1% | 0.08 | 6 / 472 |
adrenal gland | 3% | 1.85 | 8 / 258 | 32% | 1.33 | 74 / 230 |
breast | 24% | 19.71 | 112 / 459 | 8% | 0.24 | 91 / 1118 |
kidney | 12% | 10.31 | 11 / 89 | 16% | 0.30 | 145 / 901 |
ovary | 26% | 30.24 | 47 / 180 | 1% | 0.02 | 5 / 430 |
intestine | 8% | 6.11 | 82 / 966 | 18% | 0.60 | 93 / 527 |
prostate | 24% | 17.66 | 58 / 245 | 1% | 0.02 | 7 / 502 |
thymus | 19% | 12.59 | 124 / 653 | 4% | 0.07 | 26 / 605 |
tonsil | 0% | 0 | 0 / 0 | 4% | 0.06 | 2 / 45 |
muscle | 2% | 1.42 | 15 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 1% | 0.01 | 1 / 80 |
liver | 0% | 0 | 0 / 226 | 1% | 0.04 | 4 / 406 |
heart | 1% | 0.36 | 7 / 861 | 0% | 0 | 0 / 0 |
spleen | 0% | 0.22 | 1 / 241 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0014059 | Biological process | regulation of dopamine secretion |
GO_0042756 | Biological process | drinking behavior |
GO_0071466 | Biological process | cellular response to xenobiotic stimulus |
GO_0071502 | Biological process | cellular response to temperature stimulus |
GO_0050795 | Biological process | regulation of behavior |
GO_0045471 | Biological process | response to ethanol |
GO_0032229 | Biological process | negative regulation of synaptic transmission, GABAergic |
GO_0042220 | Biological process | response to cocaine |
GO_0071312 | Biological process | cellular response to alkaloid |
GO_0046849 | Biological process | bone remodeling |
GO_0007268 | Biological process | chemical synaptic transmission |
GO_0007193 | Biological process | adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway |
GO_0099171 | Biological process | presynaptic modulation of chemical synaptic transmission |
GO_0099509 | Biological process | regulation of presynaptic cytosolic calcium ion concentration |
GO_0007187 | Biological process | G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger |
GO_0002031 | Biological process | G protein-coupled receptor internalization |
GO_0014063 | Biological process | negative regulation of serotonin secretion |
GO_0007198 | Biological process | adenylate cyclase-inhibiting serotonin receptor signaling pathway |
GO_0042310 | Biological process | vasoconstriction |
GO_0051385 | Biological process | response to mineralocorticoid |
GO_1904707 | Biological process | positive regulation of vascular associated smooth muscle cell proliferation |
GO_2000300 | Biological process | regulation of synaptic vesicle exocytosis |
GO_0014053 | Biological process | negative regulation of gamma-aminobutyric acid secretion |
GO_0007205 | Biological process | protein kinase C-activating G protein-coupled receptor signaling pathway |
GO_0051967 | Biological process | negative regulation of synaptic transmission, glutamatergic |
GO_0005886 | Cellular component | plasma membrane |
GO_0042734 | Cellular component | presynaptic membrane |
GO_0030425 | Cellular component | dendrite |
GO_0044305 | Cellular component | calyx of Held |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0098666 | Cellular component | G protein-coupled serotonin receptor complex |
GO_0099154 | Cellular component | serotonergic synapse |
GO_0099626 | Molecular function | voltage-gated calcium channel activity involved in regulation of presynaptic cytosolic calcium levels |
GO_0030594 | Molecular function | neurotransmitter receptor activity |
GO_0051378 | Molecular function | serotonin binding |
GO_0004993 | Molecular function | G protein-coupled serotonin receptor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | HTR1B |
Protein name | 5-hydroxytryptamine receptor 1B (5-HT-1B) (5-HT1B) (S12) (Serotonin 1D beta receptor) (5-HT-1D-beta) (Serotonin receptor 1B) 5-hydroxytryptamine receptor 1B (5-HT-1B) (5-HT1B) (Serotonin receptor 1B) |
Synonyms | hCG_32414 HTR1DB |
Description | FUNCTION: G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. Arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Regulates the release of 5-hydroxytryptamine, dopamine and acetylcholine in the brain, and thereby affects neural activity, nociceptive processing, pain perception, mood and behavior. Besides, plays a role in vasoconstriction of cerebral arteries. . FUNCTION: G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. Arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Regulates the release of 5-hydroxytryptamine, dopamine and acetylcholine in the brain, and thereby affects neural activity, nociceptive processing, pain perception, mood and behavior. Besides, plays a role in vasoconstriction of cerebral arteries. . |
Accessions | P28222 ENST00000369947.5 X5D7I5 |